China Medical Technologies: the end of the story?

On June 27, an analyst suggested that CMEDY (former CMED) shareholders should take profits as the stock had soared to $10 (from, essentially, the penny-stock region). They sure should have - except that many probably did not have a chance to, as the next day SEC suspended trading in this stock (which had been delisted from NASDAQ's main board in February, and has been traded on the pink sheets since then). Supposedly, the suspension is just for two weeks - but I somehow I am guessing that even if trading indeed resumes after July 13, there won't be much "profits" to take anymore...

No comments:

Post a Comment